If you don't know about this stock, it is Northfield Laboratories. Their newest product, Polyheme tm, is a blood substitute. Manufactured from old blood stores, this product has unlimited shelf life and doesn't need to be typed. Several hospitals and emergency vehicles are using this product around the country with complete success. FDA approval is scheduled for the fall. At the present time, price is at low since it took off in the spring. Now is the time to buy. This stock should be in the $100 range when approval comes out. DD will follow
Posted by noahltl on :
olyHeme® is a solution of chemically modified hemoglobin derived from human blood. Hemoglobin is the oxygen-carrying component of the human red blood cell. Northfield purchases donated blood from The American Red Cross and Blood Centers of America for use as the starting material for PolyHeme. The company uses a proprietary process of separation, filtration and chemical modification to produce PolyHeme. Hemoglobin is first extracted from red blood cells and filtered to remove impurities. The purified hemoglobin is next chemically modified using a multi-step process to create a polymerized form of hemoglobin designed to avoid the undesirable effects historically associated with hemoglobin-based blood substitutes, including vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. The modified hemoglobin is then incorporated into a solution which can be administered as an alternative to transfused blood. One unit of PolyHeme contains 50 grams of modified hemoglobin, approximately the same amount of hemoglobin delivered by one unit of transfused blood.
Posted by noahltl on :
NORTHFIELD LABORATORIES ANNOUNCES PATIENT ENROLLMENT IN PHASE III URBAN AMBULANCE TRIAL TO BEGIN
EVANSTON, IL – DECEMBER 22, 2003—Northfield Laboratories Inc. (NASDAQ: NFLD) announced today that it has received clearance to begin patient enrollment in its pivotal Phase III urban ambulance trial with PolyHeme?, the Company’s oxygen-carrying blood substitute.
“I am gratified to report that Northfield has received notification of the first full approval by an Institutional Review Board (IRB) to proceed with patient enrollment in this trial,” said Steven A. Gould, M.D., Chairman and Chief Executive Officer. “This is a key accomplishment for Northfield, attributable to the diligence and perseverance of the many individuals involved in the challenge of embarking on such a complex trial. We anticipate multiple other final IRB approvals in the near future.
“We have scheduled a site initiation visit prior to the end of this month and patient enrollment will begin immediately thereafter,” said Dr. Gould.
The PolyHeme® urban ambulance trial is a controlled study designed to evaluate the safety and efficacy of PolyHeme® in treating severely injured and bleeding patients when blood is not immediately available. Patients meeting the eligibility criteria will be randomly assigned to receive infusions of either PolyHeme® or the current standard treatment, a saline solution. Treatment will begin before arrival at the hospital, either at the scene of the injury or in the ambulance, and continue during a 12-hour post injury period in the hospital. The study will enroll 720 patients and will be conducted at approximately 20 Level I trauma centers across the United States.
In this trial it may not be possible to obtain informed consent from the patient or a legally authorized representative due to the urgency of the situation and the extent of the injuries. The study is therefore being conducted under a federal regulation that allows research to be conducted in certain emergent, life-threatening situations using an exception from the requirement for informed consent. Authorization to proceed with patient enrollment under this regulation signifies that the IRB has completed its oversight and evaluation of the public disclosure and community consultation process that is required, as well as its comprehensive review of the study protocol.
About Northfield Laboratories Northfield Laboratories Inc. is the leader in developing an oxygen- carrying blood substitute, PolyHeme(r), for the treatment of urgent, large volume blood loss in trauma and surgical settings. PolyHeme(r) is a solution of chemically modified human hemoglobin which simultaneously restores lost blood volume and hemoglobin levels and can be rapidly and massively infused. PolyHeme(r) requires no cross matching. It is immediately available and compatible with all blood types. It has an extended shelf life of over 12 months.
Northfield Laboratories, Inc. Nov-11-2002 NEW STORY Northfield Laboratories Receives FDA Response on Proposed Ambulance Trail Oct-16-2002 Northfield Laboratories Proposes First Ambulance Blood Substitute Trial Oct-16-2002 Northfield Laboratories Reports First-Quarter Results Oct-9-2002 Northfield Laboratories Sets Date and Time for First Quarterly Conference Call Oct-8-2002 Leading Trauma Surgeon Declares 'The Future Is Now' for Blood Substitutes Oct-4-2002 Northfield Laboratories Collaborates With U.S. Army on PolyHeme(TM) Treatment IND Oct-3-2002 Northfield Announces Certification of Annual Meeting Results Sep-30-2002 Northfield Updates Shareholders Regarding Final Annual Meeting Results Sep-27-2002 PolyHeme Data Presented at the 62nd Annual Meeting of the American Association For the Surgery of Trauma Sep-24-2002 Northfield Announces Delay In Finalizing Annual Meeting Results Sep-17-2002 Northfield Announces Annual Meeting Voting Results Sep-13-2002 Northfield Announces Preliminary Results Of Board Elections Sep-12-2002 Northfield Encourages Shareholders To Participate In Annual Meeting Sep-12-2002 Northfield Responds to False Accusations by C. Robert Coates Sep-12-2002 Webcast Alert: Northfield Laboratories Inc. Announces 2002 Annual Meeting Of Stockholders Webcast Friday September 13, 2002 at 11:00 am EDT Sep-4-2002 Northfield to Webcast Annual Meeting Live Aug-30-2002 Northfield CEO Sends Letter to Shareholders Aug-30-2002 Northfield Responds to Claims of Dissident Shareholder Aug-29-2002 Northfield Builds Support for PolyHeme in Medical and Scientific Communities Aug-22-2002 Northfield Questions Credibility Of Dissident Director Nominees Aug-9-2002 Northfield Laboratories Urges Shareholders to Review Proxy Materials And Return Blue Proxy Cards Immediately Aug-1-2002 Northfield Laboratories Urges Caution Regarding Dissident Shareholder Jul-24-2002 Northfield Laboratories Announces Board and Management Changes Jul-11-2002 Northfield Laboratories Receives Director Nominations Jun-5-2002 Northfield Laboratories Trauma Data to Be Published by The Journal of The American College Of Surgeons May-15-2002 Northfield Laboratories Comments on Stock Activity May-9-2002 Northfield Laboratories Presents at Deutsche Banc Alex. Brown Healthcare Conference May-7-2002 Northfield Laboratories To Present At Deutsche Banc Alex. Brown Healthcare Conference Apr-15-2002 Northfield Laboratories Reports Fiscal 2002 Third Quarter Results Jan-11-2002 Northfield Laboratories Reports Fiscal 2002 Second Quarter Results Dec-21-2001 Northfield Laboratories to Schedule Meeting With FDA to Discuss Application Nov-19-2001 Northfield Labs Receives FDA Comments on Application For Blood Substitute Oct-16-2001 Northfield Laboratories Reports Fiscal 2002 First Quarter Results Oct-11-2001 Northfield Labs Trauma Data Establish PolyHeme's Remarkable Life-Sustaining Capacity as Blood Substitute Sep-4-2001 Northfield Discusses Strength of Data and FDA Application Aug-28-2001 Northfield Laboratories Invites You to Listen to Its Annual Business Update On The Web Aug-28-2001 Northfield Laboratories Submits Biologics License Application to FDA For Approval of Its Blood Substitute, PolyHeme(TM) Aug-20-2001 Northfield Confirms Annual Meeting Date as August 31; Lawsuit to Postpone Meeting Dismissed Aug-17-2001 Northfield Laboratories Sees No Merit in Suit to Postpone Annual Meeting Aug-16-2001 Northfield Intends to Submit FDA Application Before Labor Day; Data Analysis For Application Complete Aug-3-2001 Northfield Laboratories Reports Fiscal 2001 Results; Annual Meeting Set For Late August May-11-2001 Northfield Laboratories Discussed Regulatory Statusa and Product Advantages At Deutsche Banc Alex. Brown Healthcare Conference May-8-2001 Northfield Laboratories to Webcast Presentation at Deutsche Banc Alex Brown Healthcare Conference Apr-17-2001 Northfield Laboratories Reports Fiscal 2001 Third Quarter Results Jan-12-2001 Northfield Laboratories Reports Fiscal 2001 Second Quarter Results Nov-7-2000 Northfield Laboratories Presents Business and Clinical Updates At Investor and Scientific Forums Oct-18-2000 Northfield Laboratories Reports Fiscal 2001 First Quarter Results Oct-12-2000 Northfield Laboratories' Management Enthusiastic About Future Prospects Oct-9-2000 Northfield Laboratories 2000 Annual Meeting This Week; Business Update Accessible Online Sep-26-2000 Northfield Labs and C. Robert Coates and Management Insights Reach Agreement Aug-25-2000 Northfield Laboratories Reports Fiscal 2000 Results; To Host Annual Meeting Online Jul-28-2000 Northfield Laboratories Sets Annual Meeting Date Apr-18-2000 Northfield Laboratories Reports Fiscal 2000 Third Quarter Results Jan-14-2000 Northfield Laboratories Reports Fiscal 2000 Second Quarter Results Oct-20-1999 Northfield Laboratories Reports Results for First Quarter Aug-30-1999 Northfield Laboratories Reports Fiscal 1999 Results May-4-1999 Northfield Labs Reports Results of Blood Substitute Research; Tells HHS Committee Polyheme Improves Survival in Trauma Apr-29-1999 Northfield Labs to Present Results to Health and Human Services Committee On Blood Safety and Availability Apr-15-1999 Northfield Laboratories Reports Fiscal 1999 Third Quarter Results Oct-19-1998 Northfield Laboratories Reports Results for First Quarter Sep-2-1998 Northfield Laboratories Reports Fiscal 1998 and Fourth Quarter Results Aug-12-1998 Northfield Asked to Expand Patient Numbers in Phase III Trials in Elective Surgery; May-12-1998 Northfield Laboratories to Start European Trials of Blood Substitute With Pharmacia & Upjohn AB May-8-1998 Northfield Laboratories Names David A. Savner Director Jan-21-1998 Northfield Laboratories Reports Second Quarter Results; Phase III Trials of Blood Substitute Continue Oct-16-1997 Northfield Reports Clinical Success to the American College of Surgeons Oct-15-1997 Northfield Laboratories Reports Results For First Quarter Sep-4-1997 Northfield Laboratories Initiates Phase III Trials of Blood Substitute; Reports Results for Fiscal Year May-6-1997 Northfield Laboratories Enters Home Stretch For Blood Substitute Product Apr-16-1997 Northfield Laboratories Reports Results For Third Quarter Apr-2-1997 Northfield Laboratories Cleared For Phase III Blood Substitute Trials; First To Enter Phase III At Large Doses
Posted by casico on :
i know Several people from this company... They are looking for jobs...take that for what it is worth
Posted by mr.meoff on :
What is that suppose to mean? I have looked for a job before, when there was nothing wrong with the company. I was looking for advancement
Posted by noahltl on :
NOrthfield was updated to NASDAQ yesterday. This company has nothing but big green in its future.
Posted by noahltl on :
Still making a steady climb up. Now at $13.00. This stock was brought down by a recent issue at $12 while it was trading around 15 to raise funds for preparation for FDA approval. It normally trades around 15 but has seen 19 this spring. The low is artificial and it will continue to rise. When FDA approval comes out in fall the sky's the limit.